the most known disorder in inflammatory rheumatological classification is Rheumatoid Arthritis which is autoimmune in nature, starting when the inflammatory and immune systems interact with each other to lead to the destruction of self-cartilage and bone. Although the specific cause of rheumatoid arthritis is unknown, many studies and explanations involved in the generation of the disorder have been recognized and some of these have been identified as important sources for therapeutic studies and drug development. It has long been suggested that rheumatoid arthritis could be triggered by infectious agents mainly bacteria, the researchers found that 75% of people with new-onset, untreated rheumatoid arthritis had bacterium Prevotella copri in their intestinal microbiome, but proof of this is still lacking. According to clinical trials and research, rheumatoid arthritis patients respond effectively to chemotherapeutic drugs specifically that have antibiotic activity or are derived from antibiotics. The most therapeutic pathways were obtained by drug development are divided into three categories according to state of disease, for example in long-term aggressive disease two pathways are involved, disease- modifying anti-rheumatic drugs (DMARDs) such as methotrexate, hydroxychloroquine, sulfasalazine and leflunomide and corticosteroids such as prednisone. In acute forms of disease, known as acute flares, The third major therapeutic pathway can be involved NSAIDs with short-term glucocorticoids use. Interestingly in this respect, a relatively new class of drugs called Janus kinases inhibitors (JAK Inhibitors) such as tofacitinib, baricitinib and upadacitinib.